On February 16, 2021 Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE technology, reported that it has closed its previously announced registered direct offering with certain healthcare-focused institutional investors for the sale of 20,000,000 shares of its common stock for gross proceeds of $40,000,000, prior to deducting placement agent’s fees and other offering expenses (Press release, Pulmatrix, FEB 16, 2021, View Source [SID1234575113]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

The shares of common stock were offered by Pulmatrix pursuant to a "shelf" registration statement on Form S-3 (File No. 333-230225) previously filed with the Securities and Exchange Commission (the "SEC") on March 12, 2019 and declared effective by the SEC on March 15, 2019. A prospectus supplement dated February 11, 2021 and the accompanying prospectus relating to and describing the terms of the registered direct offering was filed with the SEC on February 16, 2021. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC’s website at or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at .

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On February 16, 2021 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported that it is scheduled to speak at Citi’s 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference (Press release, Quest Diagnostics, FEB 16, 2021, View Source [SID1234575112]). Mark Guinan, Executive Vice President & CFO will discuss the company’s vision, goals, and capital deployment strategies. The presentation is scheduled for Wednesday, February 24, 2021 at 1:30 p.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live during the conference and will be available on the company’s investor relations page which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 48 hours after the conclusion of the live event and will remain available until March 26, 2021.

On February 16, 2021 Oasmia Pharmaceutical reported that it will publish its Year-end report for the shortened financial year May 1, 2020 – December 31, 2020 on February 19, 2021, at 08.00 am CET (Press release, Oasmia, FEB 16, 2021, View Source [SID1234575111]). The company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by CEO Francois Martelet, CEO and Acting CFO Robert Maiorana. The presentation will be in English.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 16, 2021 Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, reported that it is presenting at the BIO CEO & Investor Digital Conference, 16-18th February 2021 (Press release, Tiziana Life Sciences, FEB 16, 2021, View Source [SID1234575110]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences, commented, "I look forward to sharing our exciting story with conference attendees. With the release of our topline data from our COVID-19 trial, multiple Phase 2 trial launches expected in 2021, and the potential application of Foralumab in a wide range of autoimmune and inflammatory diseases in the longer-term, we are well positioned to achieve a series of important milestones in the months and quarters ahead."

Tiziana Life Sciences presentation will be accessible on demand during the virtual event for all registered attendees.

On February 16, 2021 HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, reported that it has raised an additional $3M as part of a seed financing round led by Zoic Capital for a total seed-stage raise of $6M (Press release, HDT Bio, FEB 16, 2021, View Source [SID1234575109]). The funding will support advancing HDT Bio’s three lead products into clinical trials this year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HDT Bio CEO Steven Reed said, "These funds will keep us on track to move into the clinic with products from all three of our immune activator platform technologies. We are excited to close our seed round and to move forward with clinical development."

Neal Mody, Managing Director at Zoic Capital, commented, "This is a milestone year for HDT Bio as it transitions into clinical development with multiple assets and numerous market opportunities worldwide."

HDT three lead products are:

HDT-301, a COVID-19 RNA vaccine which uses the company’s proprietary Lipid InOrganic Nanoparticle (LION) formulation to offer simpler and cheaper manufacturing, easier deployment, and vastly lower dosing than current mRNA vaccines.

HDT-201, a RIG-I immune-stimulating protein which improves the effectiveness of immuno-oncology drugs such as checkpoint inhibitors.

HDT-104, a protein that breaks down structural defenses erected by epithelial tumors, making cancers more responsive to treatment through immunotherapy and chemotherapy.

Since its founding in 2017, HDT Bio has raised a total of $16M through a combination of non-dilutive funding, international grants, private investment, and partnership revenue.